Table 3.
Adverse events reported in ≥4% of patients
| Total patients | n=49 | |
| Patients developing adverse events | n=46 | |
| Rate of developing adverse events | 93.9% | |
| Total no of developing adverse events | n=230 | |
| Adverse event name (PT) | No of patients | Rate (%) |
| Headache | 16 | 32.7 |
| Nasopharyngitis | 14 | 28.6 |
| Rash | 6 | 12.2 |
| Contusion | 5 | 10.2 |
| Upper respiratory tract inflammation | 4 | 8.2 |
| Diarrhoea | 3 | 6.1 |
| Chronic inflammatory demyelinating polyneuropathy | 3 | 6.1 |
| Erythema | 3 | 6.1 |
| Elevation of aspartate aminotransferase | 3 | 6.1 |
| Sense of fatigue | 3 | 6.1 |
| Pruritus | 2 | 4.1 |
| Abrasion | 2 | 4.1 |
| Influenza | 2 | 4.1 |
| Periodontitis | 2 | 4.1 |
| Pharyngitis | 2 | 4.1 |
| Inguinal hernia | 2 | 4.1 |
| Nausea | 2 | 4.1 |
| Elevation of alanine aminotransferase | 2 | 4.1 |
| Reduction of lymphocyte count | 2 | 4.1 |
| Anthropod bite | 2 | 4.1 |
Medical dictionary for Regulatory Activities (MedDRA), V.18.0.